Leeward Investments LLC MA Decreases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Leeward Investments LLC MA cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 142,395 shares of the medical equipment provider’s stock after selling 16,903 shares during the quarter. Leeward Investments LLC MA owned 0.06% of Hologic worth $11,600,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the 3rd quarter valued at about $25,000. Innealta Capital LLC purchased a new position in shares of Hologic during the 2nd quarter worth about $25,000. iA Global Asset Management Inc. bought a new position in Hologic during the 1st quarter valued at about $37,000. Sunbelt Securities Inc. bought a new stake in Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of Hologic stock opened at $80.49 on Thursday. The firm has a market cap of $18.70 billion, a PE ratio of 24.17, a price-to-earnings-growth ratio of 3.03 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 52 week low of $66.93 and a 52 week high of $84.67. The business’s fifty day simple moving average is $81.05 and its 200-day simple moving average is $78.12.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

HOLX has been the topic of several research analyst reports. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Leerink Partners lowered their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Raymond James raised their target price on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Mizuho reduced their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $89.25.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.